Acurx Pharmaceuticals Files 8-K on Shareholder Vote Matters
Ticker: ACXP · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1736243
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: ACRX
TL;DR
ACRX filed an 8-K for a shareholder vote - details to follow.
AI Summary
Acurx Pharmaceuticals, Inc. filed an 8-K on June 17, 2024, to report on matters submitted to a vote of its security holders. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at 259 Liberty Avenue, Staten Island, NY 10305. The report does not contain specific financial figures or details of the vote itself.
Why It Matters
This filing indicates that Acurx Pharmaceuticals held a shareholder vote, which is a standard corporate governance event. The outcome of such votes can impact the company's strategic direction and management.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain information that immediately suggests significant financial or operational risk.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- June 17, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 259 Liberty Avenue, Staten Island, NY 10305 (address) — Address of principal executive offices
- 917-533-1469 (phone_number) — Registrant's telephone number
FAQ
What specific matters were submitted to a vote of Acurx Pharmaceuticals' security holders?
The filing does not specify the exact matters voted upon, only that matters were submitted to a vote.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 17, 2024.
In which state is Acurx Pharmaceuticals, Inc. incorporated?
Acurx Pharmaceuticals, Inc. is incorporated in Delaware.
What is the address of Acurx Pharmaceuticals' principal executive offices?
The principal executive offices are located at 259 Liberty Avenue, Staten Island, NY 10305.
What is the telephone number for Acurx Pharmaceuticals, Inc.?
The company's telephone number is (917) 533-1469.
Filing Stats: 591 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-06-17 16:14:40
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ACXP The Nasdaq Stock Mar
Filing Documents
- tm2417425d1_8k.htm (8-K) — 29KB
- 0001104659-24-072270.txt ( ) — 199KB
- acxp-20240617.xsd (EX-101.SCH) — 3KB
- acxp-20240617_lab.xml (EX-101.LAB) — 33KB
- acxp-20240617_pre.xml (EX-101.PRE) — 22KB
- tm2417425d1_8k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. At the close of business on April 26, 2024, the record date of the Annual Meeting of Acurx Pharmaceuticals, Inc. ("we", "us" and "our") held on June 17, 2024 (the "Annual Meeting"), there were 15,823,102 shares of common stock outstanding and entitled to vote. At the Annual Meeting, the holders of 10,648,350 shares of our common stock, or approximately 67.29% of our outstanding shares of common stock, were represented in person or by proxy and, therefore, a quorum was present. At the Annual Meeting, our stockholders considered two proposals, which are described briefly below and in more detail in our definitive Proxy Statement filed with the Securities and Exchange Commission on April 29, 2024. The final voting results for each proposal are set forth below. Proposal 1 - Election of Directors Our stockholders elected the following directors as Class III directors to hold office until the 2027 Annual Meeting of stockholders by the following votes: Nominees Shares Voted For Shares Withheld Broker Non-Votes Robert J. DeLuccia 5,235,276 576,861 4,836,213 Joseph C. Scodari 4,807,715 1,004,422 4,836,213 James Donohue 4,810,817 1,001,320 4,836,213 Proposal 2 - Ratification of Independent Registered Public Accounting Firm Our stockholders ratified the appointment of CohnReznick LLP as our independent auditors for the fiscal year ending December 31, 2024 by the following votes: Shares Voted For Shares Voted Against Abstentions Broker Non-Votes 10,542,955 69,261 36,134 —
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized. Acurx Pharmaceuticals, Inc. Date: June 17, 2024 By: /s/ David P. Luci Name: David P. Luci Title: President and Chief Executive Officer